Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: MTH009
MIFTS: 57

Mouth Disease

Categories: Gastrointestinal diseases, Oral diseases
Genes Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Mouth Disease

About this section

MalaCards integrated aliases for Mouth Disease:

Name: Mouth Disease 12 15 17
Mouth Diseases 44 71
Mouth Disorders 42

Classifications:

MalaCards categories:
Anatomical: Oral diseases Gastrointestinal diseases
See all MalaCards categories (disease lists)


External Ids:

Disease Ontology 12 DOID:403
MeSH 44 D009059
NCIt 50 C27641
SNOMED-CT 67 118938008
UMLS 71 C0026636
Sources

Summaries for Mouth Disease

About this section
MedlinePlus : 42 Your mouth is one of the most important parts of your body. It has many different functions. It allows you to Take in food and drink Breathe in air Start digestion, with your teeth chewing the food you eat and your salivary glands releasing saliva to help break down the food Speak and sing Show emotion, by smiling or pouting Any problem that affects your mouth can make it hard to eat, drink, or even smile. Some common mouth problems include Cold sores - painful sores on the lips and around the mouth, caused by a virus Canker sores - painful sores in the mouth, caused by bacteria or viruses Thrush - a yeast infection that causes white patches in your mouth Leukoplakia - white patches of excess cell growth on the cheeks, gums or tongue, common in smokers Dry mouth - a lack of enough saliva, caused by some medicines and certain diseases Gum or tooth problems Bad breath Treatment for mouth disorders varies, depending on the problem. If a mouth problem is caused by some other disease, treating that disease can help. It is also important to keep your mouth clean and healthy by brushing, flossing, and not using tobacco.

MalaCards based summary : Mouth Disease, also known as mouth diseases, is related to hand, foot and mouth disease and stomatitis, and has symptoms including tinnitus, snoring and halitosis. An important gene associated with Mouth Disease is G3BP1 (G3BP Stress Granule Assembly Factor 1), and among its related pathways/superpathways are Innate Immune System and TGF-Beta Pathway. The drugs Ribavirin and Mannitol have been mentioned in the context of this disorder. Affiliated tissues include mouth, kidney and tongue, and related phenotypes are Decreased shRNA abundance (Z-score < -2) and Decreased shRNA abundance (Z-score < -2)

Disease Ontology : 12 A gastrointestinal system disease that is located in the mouth.

Sources

Related Diseases for Mouth Disease

About this section

Diseases related to Mouth Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 576)
# Related Disease Score Top Affiliating Genes
1 hand, foot and mouth disease 33.3 VDR TLR7 TLR4 TLR3 SCARB2 IL6
2 stomatitis 32.4 IL6 IL10 IFNG IFNA1 DDX58
3 disease by infectious agent 32.0 TLR7 TLR4 IL6 IL10 IFNG IFNA1
4 exanthem 31.9 IL6 IL10 IFNG IFNA1 CRP
5 encephalitis 31.8 TLR3 IRF3 IL6 IL10 DDX58
6 myocarditis 31.6 TLR4 TLR3 IL6 IL10 IFNG IFNA1
7 pulmonary edema 31.6 IL13 IL10 CRP
8 herpangina 31.5 TP53 TLR7 TLR4 TLR3 IRF3 IL6
9 poliomyelitis 31.5 TLR3 SCARB2 IL10 IFNG IFNA1 EIF4G1
10 vaccinia 31.3 TP53 STAT1 IRF3 IL6 IFNA1 EIF4G1
11 viral infectious disease 31.2 TLR7 TLR4 TLR3 STAT1 IRF3 IL6
12 dermatitis 31.2 STAT1 IL6 IL13 IL10 IFNG
13 chickenpox 31.2 STAT1 IL6 IL10 IFNG IFNA1 CRP
14 rhinitis 31.2 IL6 IL13 IL10 IFNG
15 plague 31.1 TLR4 IL6 IL10 DDX58
16 brucellosis 31.1 TLR4 IL6 IL13 IL10 IFNG CRP
17 allergic disease 31.1 TLR7 TLR4 IL6 IL13 IFNG
18 meningitis 31.0 TLR4 IL6 IL13 IL10 IFNG CRP
19 meningoencephalitis 31.0 IL6 IL10 CRP
20 aphthous stomatitis 31.0 TLR4 IL6 IL10 IFNG
21 hepatitis a 31.0 TLR4 TLR3 IL10 IFNG IFNA1
22 avian influenza 31.0 IL6 IFNA1 DDX58
23 measles 31.0 TLR7 TLR4 TLR3 STAT1 IRF3 IL6
24 diarrhea 30.9 TLR4 IL6 IL13 IL10 IFNG IFNA1
25 dermatitis, atopic 30.9 TLR4 IL6 IL13 IL10 IFNG
26 viral encephalitis 30.9 TLR3 IL6 IL10 IFNA1
27 skin disease 30.9 VDR TP53 IL6 IL13 IL10 IFNG
28 nervous system disease 30.9 TP53 TLR4 IL6 IL10 IFNG CRP
29 chorioretinitis 30.9 IL6 IL10 IFNG CRP
30 respiratory failure 30.9 TLR4 IL6 IL13 IL10 CRP
31 trypanosomiasis 30.8 STAT1 IL6 IL10 IFNG
32 venezuelan equine encephalitis 30.8 STAT1 IFNG IFNA1
33 rabies 30.8 TLR3 STAT1 IRF3 IFNA1 DDX58
34 japanese encephalitis 30.8 TLR7 TLR3 STAT1 IRF3 IFNA1 DDX58
35 influenza 30.7 TLR7 TLR3 STAT1 IRF3 IL6 IFNG
36 endocarditis 30.7 IL6 IL10 IFNG CRP
37 conjunctivitis 30.7 TLR3 IL6 IL13 IL10 IFNG
38 tetanus 30.7 IL6 IL13 IL10 IFNG CRP
39 acute pancreatitis 30.7 TLR4 IL6 IL10 CRP
40 hepatitis e 30.7 TLR3 IFNG DDX58
41 herpes simplex 30.6 TLR3 STAT1 IRF3 IFNA1 DDX58
42 hepatitis b 30.6 TP53 TLR4 TLR3 STAT1 IL6 IFNG
43 severe acute respiratory syndrome 30.6 TLR4 STAT1 IRF3 IL6 IL10 IFNG
44 periodontitis 30.5 VDR TLR4 IL6 IL10 IFNG CRP
45 enterocolitis 30.5 TLR4 IL6 IL10 CRP
46 acquired immunodeficiency syndrome 30.5 TP53 IL6 IL10 IFNG IFNA1 CRP
47 bronchopneumonia 30.5 TLR4 IL6 IL10 CRP
48 perinatal necrotizing enterocolitis 30.5 TLR4 IL6 IL10 CRP
49 tick-borne encephalitis 30.5 TLR3 IL10 IFNA1 DDX58
50 fasciitis 30.5 TP53 IL6 IFNG IFNA1

Graphical network of the top 20 diseases related to Mouth Disease:



Diseases related to Mouth Disease
Sources

Symptoms & Phenotypes for Mouth Disease

About this section

UMLS symptoms related to Mouth Disease:


tinnitus, snoring, halitosis, sore throat, coughing, vertigo/dizziness, equilibration disorder, oral manifestations

GenomeRNAi Phenotypes related to Mouth Disease according to GeneCards Suite gene sharing:

26 (show all 19)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased shRNA abundance (Z-score < -2) GR00366-A-113 9.62 TLR4
2 Decreased shRNA abundance (Z-score < -2) GR00366-A-114 9.62 EIF4G1 TLR4
3 Decreased shRNA abundance (Z-score < -2) GR00366-A-128 9.62 IL10
4 Decreased shRNA abundance (Z-score < -2) GR00366-A-132 9.62 IL10
5 Decreased shRNA abundance (Z-score < -2) GR00366-A-133 9.62 EIF4G1
6 Decreased shRNA abundance (Z-score < -2) GR00366-A-166 9.62 EIF4G1
7 Decreased shRNA abundance (Z-score < -2) GR00366-A-169 9.62 TLR4
8 Decreased shRNA abundance (Z-score < -2) GR00366-A-173 9.62 IL10
9 Decreased shRNA abundance (Z-score < -2) GR00366-A-179 9.62 IL10
10 Decreased shRNA abundance (Z-score < -2) GR00366-A-180 9.62 CRP
11 Decreased shRNA abundance (Z-score < -2) GR00366-A-185 9.62 EIF4G1
12 Decreased shRNA abundance (Z-score < -2) GR00366-A-25 9.62 IL10
13 Decreased shRNA abundance (Z-score < -2) GR00366-A-34 9.62 IL10
14 Decreased shRNA abundance (Z-score < -2) GR00366-A-38 9.62 EIF4G1
15 Decreased shRNA abundance (Z-score < -2) GR00366-A-49 9.62 CRP
16 Decreased shRNA abundance (Z-score < -2) GR00366-A-68 9.62 CRP
17 Decreased shRNA abundance (Z-score < -2) GR00366-A-8 9.62 EIF4G1
18 Decreased shRNA abundance (Z-score < -2) GR00366-A-80 9.62 IL10
19 Decreased shRNA abundance (Z-score < -2) GR00366-A-89 9.62 CRP

MGI Mouse Phenotypes related to Mouth Disease:

46 (show all 17)
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.4 CRP DDX58 G3BP2 IFNG IL10 IL13
2 hematopoietic system MP:0005397 10.39 DDX58 IFNG IL10 IL13 IL17F IL6
3 cardiovascular system MP:0005385 10.38 CRP G3BP1 IFNG IL10 IL6 IRF3
4 immune system MP:0005387 10.38 CRP DDX58 IFNG IL10 IL13 IL17F
5 cellular MP:0005384 10.37 DDX58 G3BP1 IFNG IL10 IL13 IL6
6 growth/size/body region MP:0005378 10.35 DDX58 G3BP1 IFNG IL10 IL13 IL17F
7 mortality/aging MP:0010768 10.31 DDX58 G3BP1 G3BP2 IFNG IL10 IL13
8 digestive/alimentary MP:0005381 10.29 DDX58 IFNG IL10 IL13 IL17F IL6
9 integument MP:0010771 10.11 IFNG IL10 IL13 IL6 NOTCH1 STAT1
10 hearing/vestibular/ear MP:0005377 10.07 G3BP1 IL13 NOTCH1 SCARB2 TLR4 TP53
11 muscle MP:0005369 10.07 IFNG IL10 IL13 IL6 NOTCH1 STAT1
12 liver/biliary system MP:0005370 10.03 DDX58 IFNG IL10 IL6 NOTCH1 STAT1
13 nervous system MP:0003631 10.03 G3BP1 IFNG IL10 IL13 IL6 NOTCH1
14 neoplasm MP:0002006 9.97 DDX58 IFNG IL10 IL6 NOTCH1 STAT1
15 renal/urinary system MP:0005367 9.81 IFNG IL6 IRF3 NOTCH1 SCARB2 TLR4
16 respiratory system MP:0005388 9.73 G3BP1 IFNG IL10 IL13 IL17F IL6
17 skeleton MP:0005390 9.36 IFNG IL10 IL13 IL17F IL6 NOTCH1
Sources

Drugs & Therapeutics for Mouth Disease

About this section

Drugs for Mouth Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 82)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ribavirin Approved Phase 4 36791-04-5 37542
2
Mannitol Approved, Investigational Phase 4 69-65-8 453 6251
3 Anti-Infective Agents Phase 4
4 Antimetabolites Phase 4
5 Antiviral Agents Phase 4
6 Antibodies, Blocking Phase 4
7 Immunoglobulins Phase 4
8 Antibodies Phase 4
9 Vaccines Phase 4
10 Immunologic Factors Phase 4
11
Ibuprofen Approved Phase 2 15687-27-1 3672
12
Acetaminophen Approved Phase 2 103-90-2 1983
13
Sucralfate Approved Phase 2 54182-58-0
14
Magnesium Sulfate Approved, Investigational, Vet_approved Phase 2 7487-88-9 24083
15
Vitamin A Approved, Nutraceutical, Vet_approved Phase 2 68-26-8, 11103-57-4 445354
16 Pharmaceutical Solutions Phase 2
17 Analgesics, Non-Narcotic Phase 2
18 Anti-Ulcer Agents Phase 2
19 Antacids Phase 2
20 Cyclooxygenase Inhibitors Phase 2
21 Anti-Inflammatory Agents, Non-Steroidal Phase 2
22 Antirheumatic Agents Phase 2
23 Antipyretics Phase 2
24 Anticonvulsants Phase 2
25 Anesthetics Phase 2
26 Retinol palmitate Phase 2
27 retinol Phase 2
28 Hormones Phase 2
29 Tocolytic Agents Phase 2
30 Calcium, Dietary Phase 2
31 Analgesics Phase 2
32 calcium channel blockers Phase 2
33 Anti-Arrhythmia Agents Phase 2
34
Calcium Nutraceutical Phase 2 7440-70-2 271
35
Aluminum hydroxide Approved, Investigational Phase 1 21645-51-2
36
Suramin Investigational Phase 1 145-63-1 5361
37 Antiparasitic Agents Phase 1
38 Anthelmintics Phase 1
39 Antiprotozoal Agents Phase 1
40
Nicotine Approved 54-11-5 942 89594
41 sodium fluoride Approved 7681-49-4
42
Prednisolone Approved, Vet_approved 50-24-8 5755
43 Prednisolone acetate Approved, Vet_approved 52-21-1
44
Prednisolone phosphate Approved, Vet_approved 302-25-0
45
Methylprednisolone Approved, Vet_approved 83-43-2 6741
46
Methylprednisolone hemisuccinate Approved 2921-57-5
47 Ginger Approved
48 Orange Approved
49
Fentanyl Approved, Illicit, Investigational, Vet_approved 437-38-7 3345
50
Lidocaine Approved, Vet_approved 137-58-6 3676

Interventional clinical trials:

(show top 50) (show all 86)
# Name Status NCT ID Phase Drugs
1 Safety, Three Batches Consistency and Immunity Duration of the Post-marketing Inactivated Enterovirus Type 71 (EV71) Vaccine in Children Aged 6-71 Months Unknown status NCT02889497 Phase 4
2 The Safety and Immunogenicity of Enterovirus Type 71 Inactivated Vaccine (Human Diploid Cell) With Two Measles Attenuated Live Vaccine and Live Attenuated Japanese Encephalitis Vaccine at the Same Time Point in Infants (8-month-old) Unknown status NCT03296410 Phase 4
3 Study on Immunogenicity of Inactivated Enterovirus 71 (EV71) Vaccine (Human Diploid Cell, KMB-17) in Large-scale Healthy Children in China Unknown status NCT03240744 Phase 4
4 Effect and Safety of Xiao'er Jiebiao Oral Liquid in Combination With Standard Treatment on Hand-foot-mouth Disease in Pediatric Patients Completed NCT02328651 Phase 4 Ribavirin plus Xiao'er jiebiao oral liquid;Ribavirin
5 Effectiveness and Safety of Inactivated EV71 Vaccine (Human Diploid Cell) in 6-71 Months Children: an Open-label Controlled Phase â…£ Clinical Study Completed NCT03001986 Phase 4
6 A Opened，Randomized and Controlled Trial to Evaluate the Immunity and Safety of Sequential Vaccination of Two Different Commercial EV71 Inactived Vaccines in Healthy Infants Aged 6-35 Months Completed NCT03873740 Phase 4
7 A Phase IV Open-labelled, Single-centered, Stratified-randomized Clinical Trial in Zhejiang Province to Evaluate the Safety and Immunogenicity of EV71 Vaccine Developed by Sinovac Biotech Co., Ltd. Completed NCT03278132 Phase 4
8 A Randomized, Controlled Clinical Trial to Evaluate the Safety and Immunogenicity of Concomitant Administration of EV71 Vaccine With Recombinant Hepatitis B Vaccine/Group A Meningococcal Polysaccharide Vaccine Completed NCT03274102 Phase 4
9 Peri-implantitis - Regenerative Treatment With Enamel Matrix Derivative (EMD). Clinical Effects, Microbial Profiles and Molecular Mechanisms. A Randomised Controlled Pilot Study. Completed NCT02500654 Phase 4
10 A Randomized, Controlled Clinical Trial to Evaluate the Safety and Immunogenicity of Concomitant Administration of EV71 Vaccine With Measles, Mumps, and Rubella Combined Live Attenuated Vaccine/ Encephalitis Live Attenuated Vaccine Recruiting NCT04111432 Phase 4
11 Multiple Centers, Randomized, and Control Trail on the Immunogenicity and Safety of the Simultaneously Vaccination of Inactivated Enterovirus 71 Vaccine (EV71) and Seasonal Influenza Vaccine(SIV) Recruiting NCT04133584 Phase 4
12 A Comparison of Three Different Modalities in Improving Oral Hygiene in Adult Orthodontic Patients - A Randomized Controlled Trial Recruiting NCT04386421 Phase 4 Plaque disclosing tablets
13 Phase â…£ Clinical Trial, to Evaluate the Efficacy of the Enterovirus 71 (EV71) Inactivated Vaccine and Its Correlation With EV71 Antibody Level Active, not recruiting NCT03903926 Phase 4
14 A Phase IV Clinical Trial for Efficacy Evaluation for Inactivated Vaccine (Vero Cell) Against EV71: A Multicenter， Case-control Study. Enrolling by invitation NCT03582761 Phase 4
15 Three Batches Consistency, Immunity Duration and Safety of Inactivated Enterovirus 71 Vaccine Post-marketing Among Children Aged 6-35 Months in China Not yet recruiting NCT03893747 Phase 4
16 A Multiple-center Randomized Double-blind Placebo-controlled Phase 3 Clinical Trial to Assess the Efficacy and Safety of an Inactivated Vaccine (Vero Cell) Against EV71 in Chinese Children Aged 6-35 Months Completed NCT01508247 Phase 3
17 A Multicentered, Double - Blind, Randomized, and Placebo - Controlled Clinical Trial With Inactivated Enterovirus Type 71 (EV71) Vaccines Completed NCT01507857 Phase 3
18 Immunogenicity and Safety of Three Consecutive Lots of a New Inactivated Enterovirus Type 71 (EV71) Vaccine: A Double-blind, Randomized and Controlled Trial Completed NCT01636245 Phase 3
19 A Phase III Clinical Trial With Randomized, Double-blinded, Controlled Design as Well as Bridging Design to Evaluate the Safety and Immunogenicity of EV71 Vaccine in Children Aged 36-71 Months Completed NCT03909074 Phase 3
20 Sucralfate to Improve Oral Intake in Children With Infectious Oral Ulcers: a Randomized, Double-blind, Placebo-Controlled Trial Unknown status NCT03241030 Phase 2 Sucralfate;Acetaminophen;Ibuprofen
21 Periapical Bone Healing After Apicectomy With and Without Retrograde Root Filling Unknown status NCT00228280 Phase 1, Phase 2
22 A Phase II Randomized Double Blind Placebo Controlled Trial to Assess Safety and Efficacy of Velafermin for Prevention of Oral Mucositis in Hematologic Cancer Patients Receiving Autologous Stem Cell Transplant Completed NCT00323518 Phase 2 velafermin;placebo
23 A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of the Safety and Efficacy of CG53135-05 Administered Intravenously as a Single Dose for the Prevention of Oral Mucositis in Patients Receiving Autologous Hematopoietic Stem Cell Transplant Completed NCT00104065 Phase 2 CG53135-05, velafermin
24 A Randomized, Placebo-controlled, Double-blind Trial of Intravenous Magnesium Sulfate for the Management of Severe Hand, Foot and Mouth Disease With Autonomic Nervous System Dysregulation in Vietnamese Children. Completed NCT01940250 Phase 2 Magnesium Sulphate;Sterile water
25 A Phase II Clinical Trial for Inactivated Enterovirus Type 71 Vaccine (Human Diploid Cell, KMB-17 Cell) in Chinese Infants Completed NCT01512706 Phase 2
26 A Randomized, Open, Phase I/II to Evaluate the Inactivated EV 71 Vaccine Safety in Healthy Adults Followed by Safety and Immunogenicity Administered in 2 Consecutive Doses, 1 Month Apart Among Child Aged 6 to 71 Months. Completed NCT04467541 Phase 1, Phase 2
27 Phase II, Multicenter, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study of the Effects of RK-0202 on Oral Mucositis in Patients Receiving Radiation Therapy for Tumors of the Oral Cavity, Oropharynx, Nasopharynx, Salivary Glands or Supraglottic Region Completed NCT00230191 Phase 2 RK-0202
28 Evaluation of the Clinical Effects of Tooth Powder on Plaque Induced Gingivitis Completed NCT01902095 Phase 2
29 A Randomized, Double-blind, Placebo-controlled, Single-dose, Dose-escalation Study to Evaluate the Tolerance and Pharmacokinetics of Suramin Sodium in Healthy Chinese Adults Unknown status NCT03804749 Phase 1 suramin sodium
30 Intraoral Grafting of Ex Vivo Produced Oral Mucosal Composites Unknown status NCT00000111 Phase 1
31 Phase I, Double Blind, Randomized, Placebo-controlled, Dose Escalation Study to Assess the Safety and Immunogenicity of a Prophylactic Vaccine Against Enterovirus Infection in Healthy Adults Completed NCT01376479 Phase 1
32 A Phase Ia Clinical Trial for Inactivated Vaccine(Vero Cell) Against EV71 in Chinese Healthy Young Adults and Children Completed NCT01267903 Phase 1
33 A Phase I Clinical Trial for Inactivated Enterovirus Type 71 Vaccine (Human Diploid Cell, KMB-17 Cell) in Chinese Adults, Children and Infants Completed NCT01391494 Phase 1
34 A Blind, Randomized and Placebo-controlled Clinical Trial With Inactivated Enterovirus Type 71 Vaccines in Healthy Children. Completed NCT01273246 Phase 1
35 A Phase Ib Clinical Trial for Inactivated Vaccine (Vero Cell) Against EV71 in Chinese Children and Infants Completed NCT01313715 Phase 1
36 A Randomized, Double-blind, Placebo-controlled, Phase 1 Clinical Trial to Investigate the Safety and Immunogenicity of CJ-40010 After Administration in Healthy Subjects Recruiting NCT04182932 Phase 1
37 A Randomized, Double-blind, Placebo-controlled, Phase 1 Clinical Trial to Investigate the Safety and Immunogenicity of High-dose IN-B001 After Administration in Healthy Subjects Not yet recruiting NCT04637919 Phase 1
38 Validation and Dosimetry Study of [18F]-FBA-A20FMDV2 PET Ligand for Alpha(V)beta6 in Healthy Subjects and in the Lungs of Idiopathic Pulmonary Fibrosis (IPF) Subjects (PETAL Study) Terminated NCT02052297 Phase 1
39 A Clinical Trial to Evaluate the Effectiveness and Safety of Xiyanping Injection in the Treatment of Mild Type of Hand, Foot, and Mouth Disease Unknown status NCT01182025 Xiyanping Injection;Xiyanping Injection with western medicine
40 A Multi-Center Clinical Trial To Evaluate Chinese Herbal Medicines in the Treatment of Severe Hand-foot-mouth Disease Unknown status NCT01145664 Herbal concentrate-granules plus western therapy;Reduning Injection plus western therapy;Western therapy
41 A Clinical Trial To Evaluate Reduning Injection in the Treatment of Mild Type of Hand, Foot, and Mouth Disease Unknown status NCT01175915
42 Burning Mouth Disorder (BMD) - a Neuropathic Pain Disorder? An Investigation Using Qualitative and Quantitative Sensory Testing (QST) Unknown status NCT00504387
43 Efficacy of Tobacco Cessation for Improving Oral Diseases - Multicenter Prospective Trial Unknown status NCT02737176
44 Caries Prophylaxis With Flairesse Fluoride Varnish in South African School Children Participating in the LiveSmart Oral Health Program That is Conducted by the Dental Wellness Trust - a Controlled Clinical Trial Unknown status NCT03429829
45 Prevalence of Oral Findings in Adult Patients With Chronic Kidney Disease '' Cross Sectional 2 " Unknown status NCT03082365
46 Prevalence of Oral Findings in Adult Patients With Chronic Kidney Disease "Cross Sectional Unknown status NCT03074188
47 Prevalence of Oral Mucosal Alterations in a Sample of Egyptian Patients With Mucocutaneous Ocular Disorders: A Hospital Based Cross Sectional Study Unknown status NCT03679988
48 An Open-labelled, Multicentered, Follow-up Study for a Phase III, Efficacy Trial to Evaluate the Two-year Efficacy, Safety, and Immune Persisitence of Inactivated Enterovirus Type 71 (EV71) Vaccine Completed NCT02001233
49 Study on Dynamic Changes of the Maternal Anti-EV71 and Anti-CVA16 Antibody Levels in Infants and Young Children Completed NCT01255124
50 A Prospective Cohort Study Evaluating Prognostic Indicators and Sequelae Following Severe Hand Foot and Mouth Disease Completed NCT02066714

Search NIH Clinical Center for Mouth Disease

Inferred drug relations via UMLS 71 / NDF-RT 51 :


Lidocaine
LIDOCAINE HCL PWDR
Lidocaine Hydrochloride
LIDOCAINE PWDR

Cochrane evidence based reviews: mouth diseases

Sources

Genetic Tests for Mouth Disease

About this section
Sources

Anatomical Context for Mouth Disease

About this section

The Foundational Model of Anatomy Ontology organs/tissues related to Mouth Disease:

19
Mouth

MalaCards organs/tissues related to Mouth Disease:

40
Kidney, Tongue, Skin, T Cells, Endothelial, Bone, Whole Blood
Sources

Publications for Mouth Disease

About this section

Articles related to Mouth Disease:

(show top 50) (show all 9967)
# Title Authors PMID Year
1
IgG4-Related Disease of the Oral Cavity. Case Series from a Large Single-Center Cohort of Italian Patients. 42
33167472 2020
2
Erythema multiforme: integrating the superfluous diagnosis to a veracious conclusion (case report). 42
33425162 2020
3
Head and neck cancer therapy-related oral manifestation management in the COVID-19 pandemic: a critical review. 42
33146316 2020
4
Genetic variation and evolution of foot-and-mouth disease virus serotype A in relation to vaccine matching. 61
33526282 2021
5
The risk factor assessment of the spread of foot-and-mouth disease in mainland China. 61
33346020 2021
6
Herpes Simplex Virus Infection in Infants: 13 Year Evaluation (2005-2017) of Laboratory Confirmed Cases in Queensland, Australia. 61
33165280 2021
7
Secure Sheep and Wool Supply Plan for Continuity of Business. 61
33541700 2021
8
Sulfonated azo dyes enhance the genome release of enterovirus A71 VP1-98K variants by preventing the virions from being trapped by sulfated glycosaminoglycans at acidic pH. 61
33422703 2021
9
FMD empty capsids combined with the Immunostimulant Particle Adjuvant -ISPA or ISA206 induce protective immunity against Foot and Mouth Disease Virus. 61
33596405 2021
10
Challenges in foot-and-mouth disease virus strain selection as an input to attain broad vaccine intraserotype cross-protection. 61
33455492 2021
11
Foot-and-mouth disease virus infection in the domestic dog (Canis lupus familiaris), Iran. 61
33526020 2021
12
Removal of 3C protease from the 3ABC improves expression, solubility, and purification of the recombinant 3AB of foot-and-mouth disease virus. 61
33400101 2021
13
Investigation of the Optimal Medium and Application Strategy for Foot-and-mouth Disease Vaccine Antigen Production. 61
33544957 2021
14
Efficient protection against Asia1 type foot-and-mouth disease using a chimeric vaccine strain suitable for East Asia. 61
33418393 2021
15
Structural and molecular basis for foot-and-mouth disease virus neutralization by two potent protective antibodies. 61
33599962 2021
16
Monoclonal antibodies against foot-and-mouth disease virus RNA polymerase for detection of virus infection. 61
33200459 2021
17
Enhanced immunogenicity of foot and mouth disease DNA vaccine delivered by PLGA nanoparticles combined with cytokine adjuvants. 61
33592449 2021
18
Harnessing the power of foot-and-mouth-disease virus for targeting integrin alpha-v beta-6 for the therapy of cancer. 61
33533659 2021
19
The goat industry in Australia: Using Bayesian network analysis to understand vulnerability to a foot and mouth disease outbreak. 61
33385617 2021
20
Foot-and-mouth disease seroprevalence and reporting behaviours in nine northern provinces in Lao PDR: The current situation and challenges for control. 61
33559340 2021
21
Uncovering targets of the Leader protease: Linking RNA-mediated pathways and antiviral defense. 61
33605051 2021
22
Functional advantages of triplication of the 3B coding region of the FMDV genome. 61
33230899 2021
23
Enterovirus 71 induces autophagy in mice via mTOR inhibition and ERK pathway activation. 61
33581126 2021
24
[Palmoplantar dermatoses in children]. 61
33580281 2021
25
An epidemiological surveillance of hand foot and mouth disease in paediatric patients and in community: A Singapore retrospective cohort study, 2013-2018. 61
33566802 2021
26
Spatiotemporal characteristics and meteorological determinants of hand, foot and mouth disease in Shaanxi Province, China: a county-level analysis. 61
33596869 2021
27
Polymorphisms in the DC-SIGN gene and their association with the severity of hand, foot, and mouth disease caused by enterovirus 71. 61
33590343 2021
28
Characterization of oral virome and microbiome revealed distinctive microbiome disruptions in paediatric patients with hand, foot and mouth disease. 61
33608551 2021
29
DNA Methylation and SNP in IFITM3 are correlated with patients with hand, foot and mouth disease caused by enterovirus 71. 61
33596480 2021
30
Antiviral peptides against Enterovirus A71 causing hand, foot and mouth disease. 61
33171280 2021
31
Prevalence of recessive infection of pathogens of hand, foot, and mouth disease in healthy people in China: A meta-analysis. 61
33607859 2021
32
[A case of hand, foot and mouth disease in adults who first diagnosed with conjunctivitis]. 61
33541056 2021
33
Natural intertypic and intratypic recombinants of enterovirus 71 from mainland China during 2009-2018: a complete genome analysis. 61
33575934 2021
34
Molecular epidemiology and recombination of Enterovirus A71 in mainland China from 1987 to 2017. 61
33608776 2021
35
A uniform quantitative enzyme-linked immunosorbent assay for Coxsackievirus A16 antigen in vaccine. 61
32750255 2021
36
Daily mean temperature and HFMD: risk assessment and attributable fraction identification in Ningbo China. 61
33547422 2021
37
Construction and characterization of an infectious cDNA clone of enterovirus 71: a rapid method for rescuing infectious virus based on stable cells expressing T7 polymerase. 61
33423081 2021
38
Recent advances in the understanding of enterovirus A71 infection: a focus on neuropathogenesis. 61
33183118 2021
39
Ginsenoside Rb1 is an immune-stimulatory agent with antiviral activity against enterovirus 71. 61
32980486 2021
40
Quantitative analysis of infection dynamics of foot-and-mouth disease virus strain O/CATHAY in pigs and cattle. 61
33481934 2021
41
Foot-and-Mouth Disease Virus Inhibits RIP2 Protein Expression to Promote Viral Replication. 61
33400090 2021
42
Epidemiological Characteristics of Foot-and-Mouth Disease in the Republic of Korea, 2014-2019. 61
33607422 2021
43
ID1 inhibits foot-and-mouth disease virus replication via targeting of interferon pathways. 61
33492759 2021
44
Bi-functional gold nanocages enhance specific immunological responses of foot-and-mouth disease virus-like particles vaccine as a carrier and adjuvant. 61
33484882 2021
45
Novel Recombinant Foot-and-Mouth Disease Virus Circulating in Vietnam. 61
33414349 2021
46
Knowledge affecting foot-and-mouth disease vaccination behavior: traditional dairy farmers in the dry zone of Sri Lanka. 61
33415503 2021
47
On-line separation and quantification of virus antigens of different serotypes in multivalent vaccines by capillary zone electrophoresis: A case study for quality control of foot-and-mouth disease virus vaccines. 61
33383242 2021
48
Foot-and-Mouth Disease Virus Evades Innate Immune Response by 3C-Targeting of MDA5. 61
33572945 2021
49
Validation of a binary ethylenimine (BEI) inactivation procedure for biosafety treatment of foot-and-mouth disease viruses (FMDV), vesicular stomatitis viruses (VSV), and swine vesicular disease virus (SVDV). 61
33248402 2021
50
Possible Action of Transition Divalent Metal Ions at the Inter-Pentameric Interface of Inactivated Foot-and-Mouth Disease Virus Provide A Simple but Effective Approach to Enhance Stability. 61
33441340 2021
Sources

Variations for Mouth Disease

About this section
Sources

Expression for Mouth Disease

About this section
Search GEO for disease gene expression data for Mouth Disease.
Sources

Pathways for Mouth Disease

About this section

Pathways related to Mouth Disease according to GeneCards Suite gene sharing:

(show top 50) (show all 57)
# Super pathways Score Top Affiliating Genes
1
Innate Immune System 65
Show member pathways
 14.02 TP53 TLR7 TLR4 TLR3 STAT1 IRF3
2
TGF-Beta Pathway 63
Show member pathways
 13.56 TP53 STAT1 IL6 IL13 IL10 IFNG
3
Akt Signaling 63
Show member pathways
 13.44 TP53 TLR7 TLR4 TLR3 STAT1 IL6
4
Cytokine Signaling in Immune system 65
Show member pathways
 13.36 TP53 STAT1 IRF3 IL6 IL17F IL13
5
PI3K-Akt signaling pathway 36
Show member pathways
 13.01 TP53 TLR4 TLR3 STAT1 NOTCH1 IRF3
6
Human cytomegalovirus infection 36
Show member pathways
 12.99 TP53 TLR4 TLR3 STAT1 IRF3 IL6
7
Allograft rejection 36 1
Show member pathways
 12.9 STAT1 IL6 IL13 IL10 IFNG IFNA1
8
Pathways in cancer 36
12.89 TP53 STAT1 NOTCH1 IL6 IL13 IFNG
9
Toll-like Receptor Signaling Pathway 36 1
Show member pathways
 12.89 TP53 TLR7 TLR4 TLR3 STAT1 IRF3
10
Herpes simplex virus 1 infection 36
12.84 TP53 TLR3 STAT1 IRF3 IL6 IFNG
11
Toll-Like receptor Signaling Pathways 64
Show member pathways
 12.76 TLR7 TLR4 TLR3 STAT1 IRF3 IL6
12
T cell receptor signaling pathway 36
Show member pathways
 12.64 TLR4 STAT1 IL6 IL10 IFNG
13
Immune response IL-23 signaling pathway 23
Show member pathways
 12.64 TP53 STAT1 IL6 IL17F IL10 IFNG
14
Cytosolic sensors of pathogen-associated DNA 65
Show member pathways
 12.6 TLR3 IRF3 IL6 IFNA1 DDX58
15
Th17 cell differentiation 36
Show member pathways
 12.6 TLR4 STAT1 NOTCH1 IL6 IL17F IL13
16
Interferon gamma signaling 65
Show member pathways
 12.59 STAT1 IRF3 IFNG IFNA1 EIF4G1 DDX58
17
Measles 36
Show member pathways
 12.56 TP53 TLR7 TLR4 TLR3 STAT1 IRF3
18
NF-kappaB Signaling 4
12.52 TLR7 TLR3 STAT1 IRF3 IL10 IFNG
19
JAK-STAT signaling pathway 36
Show member pathways
 12.47 STAT1 IL6 IL13 IL10 IFNG IFNA1
20
Toll Comparative Pathway 63
Show member pathways
 12.36 TP53 TLR4 TLR3 STAT1 IRF3 IL6
21
IL-17 Family Signaling Pathways 64
Show member pathways
 12.35 IL6 IL17F IL13 IFNG
22
Folate Metabolism 1
Show member pathways
 12.35 TP53 IL6 IFNG CRP
23
Diseases associated with the TLR signaling cascade 65
Show member pathways
 12.33 TLR7 TLR4 TLR3 IRF3 IL6
24
NOD-like receptor signaling pathway 36
12.3 TLR4 STAT1 IRF3 IL6 IFNA1
25
Toxoplasmosis 36
Show member pathways
 12.28 TLR4 STAT1 IL10 IFNG
26
Necroptosis 36
Show member pathways
 12.27 TLR4 TLR3 STAT1 IFNG IFNA1
27
Bacterial infections in CF airways 23
Show member pathways
 12.24 TLR7 TLR4 STAT1 IL6 IFNG
28
Immune response IFN alpha/beta signaling pathway 23
Show member pathways
 12.24 TP53 STAT1 IRF3 IL6 IL13 IL10
29
Tuberculosis 36
12.17 VDR TLR4 STAT1 IL6 IL10 IFNG
30
Yersinia infection 36
12.13 TLR4 IRF3 IL6 IL10
31
Colorectal Cancer Metastasis 63
12.08 TP53 TLR7 TLR4 TLR3 STAT1 IL6
32
MAPK Pathway 70
Show member pathways
 12.07 TP53 TLR7 TLR4 TLR3 STAT1 IL13
33
Spinal Cord Injury 1
12.06 TP53 TLR4 IL6 IFNG
34
Hematopoietic Stem Cell Differentiation Pathways and Lineage-specific Markers 64
12.04 NOTCH1 IL6 IL10 IFNG
35
Interleukin-4 and 13 signaling 65
12.01 TP53 STAT1 IL6 IL17F IL13 IL10
36
Amoebiasis 36
11.98 TLR4 IL6 IL10 IFNG
37
Interferon Pathway 63
11.92 STAT1 IL6 IFNG IFNA1
38
Glucocorticoid receptor regulatory network 1
11.87 TP53 STAT1 IL6 IL13 IFNG
39
Pertussis 36
11.84 TLR4 IRF3 IL6 IL10
40
Phagocytosis of Microbes 63
11.83 TLR7 TLR4 TLR3
41
Dendritic Cells Developmental Lineage Pathway 64
11.82 TLR7 IL6 IL10 IFNG
42
Innate Lymphoid Cell Differentiation Pathways 64
11.8 IL13 IL10 IFNG
43
Primary Focal Segmental Glomerulosclerosis FSGS 1
11.76 TLR4 SCARB2 NOTCH1
44
IgA-Producing B Cells in the Intestine 64
11.71 TLR4 IL6 IL10
45
Malaria 36
11.61 TLR4 IL6 IL10 IFNG
46
Photodynamic therapy-induced AP-1 survival signaling. 1
11.59 TP53 IL6 IFNG
47
Interleukin-10 signaling 65
11.57 IL6 IL13 IL10
48
Th2 Differentiation Pathway 64
11.56 NOTCH1 IL13 IL10 IFNG
49
Transcription_Role of VDR in regulation of genes involved in osteoporosis 23
11.53 VDR IL6 IFNG
50
Th17 Differentiation Pathway 64
Show member pathways
 11.46 TLR7 TLR4 TLR3 STAT1 IL6 IL17F
Sources

GO Terms for Mouth Disease

About this section

Cellular components related to Mouth Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytoplasmic stress granule GO:0010494 9.13 G3BP2 G3BP1 EIF4G1
2 receptor complex GO:0043235 8.92 VDR TLR7 TLR4 NOTCH1

Biological processes related to Mouth Disease according to GeneCards Suite gene sharing:

(show top 50) (show all 55)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of transcription, DNA-templated GO:0045893 10.17 TP53 STAT1 NOTCH1 IRF3 IL6 IL10
2 immune system process GO:0002376 10.17 TLR7 TLR4 TLR3 IRF3 IL17F G3BP2
3 positive regulation of transcription by RNA polymerase II GO:0045944 10.14 VDR TP53 TLR4 TLR3 STAT1 NOTCH1
4 negative regulation of cell proliferation GO:0008285 10.11 VDR TP53 NOTCH1 IL6 IL10
5 viral process GO:0016032 10.11 TP53 STAT1 SCARB2 IRF3 G3BP2 G3BP1
6 immune response GO:0006955 10.1 TLR7 TLR4 TLR3 NOTCH1 IL6 IL13
7 inflammatory response GO:0006954 10.09 TLR7 TLR4 TLR3 IL6 IL17F IL13
8 innate immune response GO:0045087 10.09 TLR7 TLR4 TLR3 IRF3 IL17F G3BP2
9 cytokine-mediated signaling pathway GO:0019221 10.02 TP53 STAT1 IL6 IL17F IL13 IL10
10 response to lipopolysaccharide GO:0032496 10 TLR4 NOTCH1 IRF3 IL13 IL10
11 cellular response to lipopolysaccharide GO:0071222 9.98 TLR4 IRF3 IL6 IL10
12 positive regulation of gene expression GO:0010628 9.96 VDR TP53 TLR4 TLR3 NOTCH1 IL6
13 positive regulation of inflammatory response GO:0050729 9.94 TLR7 TLR4 TLR3 IFNG
14 cellular response to mechanical stimulus GO:0071260 9.92 TLR7 TLR4 TLR3 IL13
15 positive regulation of tumor necrosis factor production GO:0032760 9.92 TLR4 TLR3 IL6 IFNG DDX58
16 interferon-gamma-mediated signaling pathway GO:0060333 9.91 TP53 STAT1 IRF3 IFNG
17 Ras protein signal transduction GO:0007265 9.89 TP53 G3BP2 G3BP1
18 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.89 IL6 IL13 IFNG
19 positive regulation of NIK/NF-kappaB signaling GO:1901224 9.89 TLR7 TLR4 TLR3
20 type I interferon signaling pathway GO:0060337 9.88 STAT1 IRF3 IFNA1
21 positive regulation of interferon-gamma production GO:0032729 9.88 TLR7 TLR4 TLR3
22 I-kappaB kinase/NF-kappaB signaling GO:0007249 9.88 TLR7 TLR4 TLR3
23 humoral immune response GO:0006959 9.88 NOTCH1 IL6 IFNG IFNA1
24 positive regulation of smooth muscle cell proliferation GO:0048661 9.87 STAT1 IL6 IL13
25 positive regulation of interleukin-1 beta production GO:0032731 9.87 TLR4 IL6 IFNG
26 positive regulation of cytokine production GO:0001819 9.86 TLR3 IL10 IFNG
27 response to exogenous dsRNA GO:0043330 9.86 TLR3 IRF3 IFNA1 DDX58
28 toll-like receptor signaling pathway GO:0002224 9.85 TLR7 TLR4 TLR3
29 positive regulation of interleukin-12 production GO:0032735 9.85 TLR4 TLR3 IFNG
30 positive regulation of interleukin-8 production GO:0032757 9.85 TLR7 TLR4 TLR3 IL6 DDX58
31 positive regulation of interleukin-10 production GO:0032733 9.84 TLR4 IL6 IL13
32 positive regulation of JAK-STAT cascade GO:0046427 9.84 NOTCH1 IL6 IL10
33 microglial cell activation GO:0001774 9.84 TLR7 TLR3 IL13 IFNG
34 TRIF-dependent toll-like receptor signaling pathway GO:0035666 9.83 TLR4 TLR3 IRF3
35 positive regulation of cytokine production involved in inflammatory response GO:1900017 9.82 TLR4 IL6 IL17F
36 necroptotic process GO:0070266 9.81 TP53 TLR4 TLR3
37 positive regulation of macrophage activation GO:0043032 9.81 TLR4 IL13 IL10
38 positive regulation of immunoglobulin production GO:0002639 9.8 IL6 IL13 IL10
39 cellular response to exogenous dsRNA GO:0071360 9.79 TLR3 IRF3 DDX58
40 positive regulation of nitric-oxide synthase biosynthetic process GO:0051770 9.78 TLR4 STAT1 IFNG
41 I-kappaB phosphorylation GO:0007252 9.77 TLR7 TLR4 TLR3
42 positive regulation of chemokine production GO:0032722 9.77 TLR7 TLR4 TLR3 IL6 IFNG
43 positive regulation of MHC class II biosynthetic process GO:0045348 9.75 TLR4 IL10 IFNG
44 positive regulation of interferon-beta production GO:0032728 9.72 TLR7 TLR4 TLR3 IRF3 DDX58
45 negative regulation of lipid storage GO:0010888 9.71 IL6 CRP
46 cytoplasmic sequestering of NF-kappaB GO:0007253 9.71 IL10 G3BP2
47 negative regulation of MyD88-independent toll-like receptor signaling pathway GO:0034128 9.7 TLR4 TLR3
48 positive regulation of interleukin-6 production GO:0032755 9.7 TLR7 TLR4 TLR3 IL6 IL17F IFNG
49 positive regulation of transcription from RNA polymerase II promoter in response to hypoxia GO:0061419 9.68 TP53 NOTCH1
50 detection of virus GO:0009597 9.68 TLR3 DDX58

Molecular functions related to Mouth Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 10.32 VDR TP53 TLR7 TLR4 TLR3 STAT1
2 identical protein binding GO:0042802 9.61 TP53 TLR4 TLR3 STAT1 NOTCH1 IRF3
3 transmembrane signaling receptor activity GO:0004888 9.55 TLR7 TLR4 TLR3 SCARB2 NOTCH1
4 double-stranded RNA binding GO:0003725 9.54 TLR7 TLR3 DDX58
5 cytokine receptor binding GO:0005126 9.43 IL17F IL13 IFNA1
6 cytokine activity GO:0005125 9.1 IL6 IL17F IL13 IL10 IFNG IFNA1
Sources

Sources for Mouth Disease

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Mar-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....